MX2023010424A - Degradadores bifuncionales de inmunoglobulina deficientes en galactosa. - Google Patents

Degradadores bifuncionales de inmunoglobulina deficientes en galactosa.

Info

Publication number
MX2023010424A
MX2023010424A MX2023010424A MX2023010424A MX2023010424A MX 2023010424 A MX2023010424 A MX 2023010424A MX 2023010424 A MX2023010424 A MX 2023010424A MX 2023010424 A MX2023010424 A MX 2023010424A MX 2023010424 A MX2023010424 A MX 2023010424A
Authority
MX
Mexico
Prior art keywords
immunoglobulins
galactose
deficient
moiety
glycan
Prior art date
Application number
MX2023010424A
Other languages
English (en)
Spanish (es)
Inventor
Gene M Dubowchik
David Spiegel
Reese M Caldwell
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2023010424A publication Critical patent/MX2023010424A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023010424A 2021-03-10 2022-03-10 Degradadores bifuncionales de inmunoglobulina deficientes en galactosa. MX2023010424A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163159383P 2021-03-10 2021-03-10
PCT/US2022/019658 WO2022192478A1 (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Publications (1)

Publication Number Publication Date
MX2023010424A true MX2023010424A (es) 2023-09-18

Family

ID=83227063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010424A MX2023010424A (es) 2021-03-10 2022-03-10 Degradadores bifuncionales de inmunoglobulina deficientes en galactosa.

Country Status (11)

Country Link
US (2) US20240309114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4304579A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024509282A (cg-RX-API-DMAC10.html)
KR (1) KR20230154900A (cg-RX-API-DMAC10.html)
CN (1) CN116997337A (cg-RX-API-DMAC10.html)
AU (1) AU2022232620A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023017702A2 (cg-RX-API-DMAC10.html)
CA (1) CA3211335A1 (cg-RX-API-DMAC10.html)
IL (1) IL305665A (cg-RX-API-DMAC10.html)
MX (1) MX2023010424A (cg-RX-API-DMAC10.html)
WO (1) WO2022192478A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12023553152A1 (en) * 2021-05-17 2024-03-11 Biohaven Therapeutics Ltd Compositions including conjugated therapy enhancers
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
CN121038815A (zh) * 2023-04-29 2025-11-28 拜奥海芬治疗学有限公司 半乳糖缺陷型免疫球蛋白的双功能降解剂
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440191B2 (en) * 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
DK2991683T3 (da) * 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
CA2946064C (en) * 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
RU2696490C2 (ru) * 2014-05-19 2019-08-02 Пфайзер Инк. Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR
CA3134610A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins

Also Published As

Publication number Publication date
US20260146106A1 (en) 2026-05-28
JP2024509282A (ja) 2024-02-29
BR112023017702A2 (pt) 2023-12-12
CA3211335A1 (en) 2022-09-15
EP4304579A4 (en) 2026-06-10
US20240309114A1 (en) 2024-09-19
IL305665A (en) 2023-11-01
KR20230154900A (ko) 2023-11-09
WO2022192478A1 (en) 2022-09-15
CN116997337A (zh) 2023-11-03
AU2022232620A1 (en) 2023-09-21
EP4304579A1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
MX2025012882A (es) Degradadores bifuncionales de inmunoglobulinas deficientes en galactosa
MX2023008000A (es) Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos.
MXPA03007144A (es) Anticuerpos monoclonales humanos para receptor fc alfa (cd89).
BR112023017702A2 (pt) Degradadores bifuncionais de imunoglobulinas deficientes em galactose
EP3941945A4 (en) ANTITROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP2) ANTIBODIES AND ANTIBODY-DRUG CONJUGATES THEREOF
NO20071717L (no) Anti-Fc-gamma-RIIB-reseptorantistoff og anvendelser av dette
MX2022016180A (es) Conjugados anticuerpo-fármaco que comprenden anticuerpos anti-b7-h3.
SG10201810743WA (en) Conjugation methods
WO2018151817A8 (en) Co-use of anti-bcma antibody and antibody-coupled t celll receptor (actr) in cancer therapy and b cell disorders
WO2020172528A8 (en) Albumin binding antibodies and use thereof
EP2570137A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
MX2023004434A (es) Anticuerpos anti-fgfr2 y metodos para usarlos.
RU2016111137A (ru) Сконструированные конъюгаты против dll3 и способы применения
WO2019215510A3 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
EP3858347A3 (en) Psma binding ligand-linker conjugates and methods for using
JP2018537410A5 (cg-RX-API-DMAC10.html)
NO20072670L (no) PLAD domene peptider med okt halveringstid i serum pa grunn av konjugering til domene antistoffer
MX2023010099A (es) Enlazadores ramificados para conjugados de anticuerpo-fármaco y métodos de uso de estos.
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
PH12022551000A1 (en) Directed conjugation technologies
MX2022010599A (es) Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
TW200607523A (en) Drug compositions, fusions and conjugates
WO2019168947A8 (en) Bifunctional proteins combining checkpoint blockade for targeted therapy
WO2006073493A3 (en) Vaccine conjugates comprising a monoclonal antibody binding to human dentritic cells and beta human chronic gonadotropin
DE69726674T2 (de) Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren